CH6824025, potent and selective DDR1 inhibitor, reduces kidney fibrosis in UUO mice.

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Yukari Yasui, Takeshi Murata, Yoshinori Tsuboi, Atsuko Murai, Naoshi Horiba
{"title":"CH6824025, potent and selective DDR1 inhibitor, reduces kidney fibrosis in UUO mice.","authors":"Yukari Yasui, Takeshi Murata, Yoshinori Tsuboi, Atsuko Murai, Naoshi Horiba","doi":"10.1124/jpet.124.002330","DOIUrl":null,"url":null,"abstract":"<p><p>Discoidin domain receptor 1 (DDR1) is a collagen receptor with tyrosine kinase activity, and its expression is enhanced in various disease conditions. Although previous research suggests that DDR1 contributes to renal disease progression, DDR1 inhibitors for renal fibrosis have yet to be developed. In this study, we used unilateral ureteral obstruction (UUO) mice to investigate whether CH6824025, a strong and selective DDR1 phosphorylation inhibitor, can improve renal fibrosis. Furthermore, we performed 10x Visium spatial transcriptomics (ST) analysis on the kidney. CH6824025 suppressed the phosphorylation of DDR1 in the kidney, and the amount of hydroxyproline, the Sirius red- and the F4/80-positive area, and the mRNA expression of fibrosis and inflammation-related genes in the kidney were significantly decreased. 10x Visium ST analysis suggested that DDR1 is mainly expressed in distal nephrons under normal conditions, but that its expression appears to increase in the injured proximal tubules in UUO mice. Comparing mRNA expression in DDR1 positive spots in the Vehicle and the CH6824025 group, oxidative phosphorylation and mitochondrial dysfunction might be improved, and pathways involved in fibrosis tended to be inhibited in the CH6824025 administration group. Downstream analysis would suggest that mRNA expression changes in the CH6824025 group contribute to the inhibition of cell movement. Taken together, our findings suggest that CH6824025 inhibited kidney fibrosis in UUO mice, which might be due to the inhibition of the migration of inflammatory cells to the injury site and the reduction of inflammation. DDR1 inhibitors are expected to be a promising treatment for renal fibrosis. <b>Significance Statement</b> The novel DDR1 inhibitor CH6824025 could ameliorate fibrosis and inflammation in UUO mice. CH6824025 would inhibit cell motility (e.g., migration) that prevents the progression of fibrosis and improves mitochondrial function in UUO mice. CH6824025 could provide a significant benefit to patients with kidney fibrosis.</p>","PeriodicalId":16798,"journal":{"name":"Journal of Pharmacology and Experimental Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology and Experimental Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1124/jpet.124.002330","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Discoidin domain receptor 1 (DDR1) is a collagen receptor with tyrosine kinase activity, and its expression is enhanced in various disease conditions. Although previous research suggests that DDR1 contributes to renal disease progression, DDR1 inhibitors for renal fibrosis have yet to be developed. In this study, we used unilateral ureteral obstruction (UUO) mice to investigate whether CH6824025, a strong and selective DDR1 phosphorylation inhibitor, can improve renal fibrosis. Furthermore, we performed 10x Visium spatial transcriptomics (ST) analysis on the kidney. CH6824025 suppressed the phosphorylation of DDR1 in the kidney, and the amount of hydroxyproline, the Sirius red- and the F4/80-positive area, and the mRNA expression of fibrosis and inflammation-related genes in the kidney were significantly decreased. 10x Visium ST analysis suggested that DDR1 is mainly expressed in distal nephrons under normal conditions, but that its expression appears to increase in the injured proximal tubules in UUO mice. Comparing mRNA expression in DDR1 positive spots in the Vehicle and the CH6824025 group, oxidative phosphorylation and mitochondrial dysfunction might be improved, and pathways involved in fibrosis tended to be inhibited in the CH6824025 administration group. Downstream analysis would suggest that mRNA expression changes in the CH6824025 group contribute to the inhibition of cell movement. Taken together, our findings suggest that CH6824025 inhibited kidney fibrosis in UUO mice, which might be due to the inhibition of the migration of inflammatory cells to the injury site and the reduction of inflammation. DDR1 inhibitors are expected to be a promising treatment for renal fibrosis. Significance Statement The novel DDR1 inhibitor CH6824025 could ameliorate fibrosis and inflammation in UUO mice. CH6824025 would inhibit cell motility (e.g., migration) that prevents the progression of fibrosis and improves mitochondrial function in UUO mice. CH6824025 could provide a significant benefit to patients with kidney fibrosis.

强效选择性 DDR1 抑制剂 CH6824025 可减少 UUO 小鼠的肾脏纤维化。
类盘素结构域受体 1(DDR1)是一种具有酪氨酸激酶活性的胶原受体,它在各种疾病中的表达都会增强。虽然之前的研究表明 DDR1 会导致肾脏疾病的进展,但用于治疗肾脏纤维化的 DDR1 抑制剂尚未开发出来。在本研究中,我们利用单侧输尿管梗阻(UUO)小鼠研究了强选择性 DDR1 磷酸化抑制剂 CH6824025 能否改善肾脏纤维化。此外,我们还对肾脏进行了 10x Visium 空间转录组学(ST)分析。CH6824025抑制了肾脏中DDR1的磷酸化,肾脏中羟脯氨酸的含量、天狼星红和F4/80阳性面积以及纤维化和炎症相关基因的mRNA表达均显著下降。10x Visium ST分析表明,在正常情况下,DDR1主要在远端肾小管中表达,但在UUO小鼠受伤的近端肾小管中,其表达似乎有所增加。比较车辆组和 CH6824025 组中 DDR1 阳性点的 mRNA 表达,CH6824025 给药组的氧化磷酸化和线粒体功能障碍可能得到改善,而纤维化相关通路则趋于抑制。下游分析表明,CH6824025 组的 mRNA 表达变化有助于抑制细胞运动。综上所述,我们的研究结果表明,CH6824025 可抑制 UUO 小鼠的肾脏纤维化,这可能是由于抑制了炎症细胞向损伤部位的迁移并减轻了炎症所致。DDR1抑制剂有望成为治疗肾脏纤维化的一种有效方法。意义声明 新型 DDR1 抑制剂 CH6824025 可改善 UUO 小鼠的纤维化和炎症。CH6824025 可抑制细胞运动(如迁移),从而防止 UUO 小鼠的纤维化进展并改善线粒体功能。CH6824025 可使肾脏纤维化患者显著受益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
115
审稿时长
1 months
期刊介绍: A leading research journal in the field of pharmacology published since 1909, JPET provides broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信